Home | Contact Us | Log In
(888) 789-6604
Report Stack
Advanced search
Account Detail 0 items in basket
Order History Total $
Saved Searches View Basket basket
Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
Publication Date Apr 2013
Publisher GBI Research
Product Type Report
Pages 124
Single User License help $ 3500.00
Site User License help $ 7000.00
Corporate User License help $ 10500.00
 

Reportstack.com does not charge credit card fee, transaction charges, extra tax or VAT on any purchase.

Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth

Summary

The leading business intelligence provider GBI Research has released its latest research report, entitled “Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth”. The report provides insights into the vaccines in the adult and adolescent vaccines market, including market forecasts up to 2018. It provides an in-depth analysis of the vaccines for the adult and adolescent market, as well as insights into the adult and adolescent vaccines market’s Research and Development (R&D) pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global adult and adolescent vaccines market. The report analyzes the market for adult and adolescent vaccines in the US, and the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. The report discusses the global pipeline for adult and adolescent vaccines across various stages of development.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

GBI Research found that the adult and adolescent vaccines market in the top seven markets was valued at $7.2 billion in 2011, increasing at a Compound Annual Growth Rate (CAGR) of 6.9% during the 2007–2011 historic period. The market is projected to witness a growth of 5.6% during the 2011–2018 forecast period to reach $10.5 billion. The growth in the adult and adolescent vaccines market is driven by increased uptake of pneumococcal vaccines such as Prevnar 13 which got approved for use in people aged 50 and older. The pneumococcal vaccines market is expected to grow at a CAGR of 19% during the forecast period and reach $1.7 billion in 2018, from $0.5 billion in 2011.

Scope

- Annualized market data for the adult and adolescent vaccines market from 2007 to 2011, forecast forward to 2018
- Analysis of the adult and adolescent vaccines market in the leading geographies of the world, which includes the US, the UK, Germany, France, Italy, Spain, and Japan
- Market characterization of the adult and adolescent vaccines market including market size and cost of vaccination
- Key drivers and barriers that have a significant impact on the market
- Coverage of pipeline molecules in various phases of vaccine development
- Competitive benchmarking of leading companies. Key companies studied in this report are GlaxoSmithKline, Sanofi, Pfizer, Merck and Novartis.
- Key M&A activities and licensing agreements that have taken place between 2009 and up to November 2012 in the global adult and adolescent vaccines market.

Reasons to buy

- Align your product portfolio to the markets with the highest growth potential
- Develop market-entry and market expansion strategies by identifying the potential regions and adult and adolescent vaccines market segments poised for strong growth
- Create a more specifically-tailored country strategy through the understanding of key drivers and barriers of the global adult and adolescent vaccines market
- Develop key strategic initiatives by understanding the key focus areas and top-selling products of leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.


Companies Mentioned

GlaxoSmithKline Sanofi Pfizer Merck Novartis

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 12
2 Adult and Adolescent Vaccines Market to 2018: Introduction 14
2.1 Overview 14
3 Adult and Adolescent Vaccines Market to 2018: Overview 15
3.1 Vaccine Preventable Diseases 15
3.1.1 Types of Vaccines 16
3.2 Recommendations for Immunization 17
3.2.1 The US 17
3.2.2 Top Five European Countries 19
3.2.3 Japan 20
3.3 Regulatory Framework 21
3.3.1 The US 21
3.3.2 Top Five European Countries 22
3.3.3 Japan 23
3.4 Vaccine Manufacturing Process 24
4 Adult and Adolescent Vaccines Market to 2018: Market Characterization and Forecast 25
4.1 Revenue Forecast 25
4.2 Market Share by Type of Vaccines 27
4.3 Market Share by Geography 28
4.4 Drivers 29
4.4.1 Adult Vaccines Segment to Drive Future Growth 29
4.4.2 High Unmet Needs 29
4.4.3 Targeting New Diseases Areas for Vaccines Likely To Drive the Market 29
4.4.4 Novel Vaccine Technologies 30
4.5 Restraints 31
4.5.1 Production Capacity Limitations 31
4.5.2 High Initial Capital Investments and Technical Expertise 31
4.5.3 Regulations Delay Vaccine Launch and Acceptance 31
5 Adult and Adolescent Vaccines Market to 2018: Influenza Vaccines 32
5.1 Disease Overview 32
5.2 Market Forecasts 33
5.2.1 The US 33
5.2.2 Top Five European Countries 34
5.2.3 Japan 36
5.3 Cost of Vaccination 37
5.3.1 The US 37
5.3.2 Top Five European Countries 38
5.3.3 Japan 38
5.4 Pipeline Analysis – Influenza Vaccines 39
6 Adult and Adolescent Vaccines Market to 2018: Tetanus, Diphtheria and Pertussis Vaccines 42
6.1 Disease Overview 42
6.2 Market Forecasts 43
6.2.1 The US 43
6.2.2 Top Five European Countries 44
6.2.3 Japan 46
6.3 Cost of Vaccination 47
6.3.1 The US 47
6.3.2 Top Five European Countries 47
6.3.3 Japan 48
6.4 Pipeline Analysis – Tetanus, Diphtheria, Pertussis (Td/Tdap) Vaccines 49
7 Adult and Adolescent Vaccines Market to 2018: Pneumococcal Vaccines 50
7.1 Disease Overview 50
7.2 Market Forecasts 51
7.2.1 The US 51
7.2.2 Top Five European Countries 53
7.2.3 Japan 55
7.3 Cost of Vaccination 56
7.3.1 The US 56
7.3.2 Top Five European Countries 56
7.3.3 Japan 57
7.4 Pipeline Analysis – Pneumococcal Vaccines 58
8 Adult and Adolescent Vaccines Market to 2018: Meningococcal Vaccines 60
8.1 Disease Overview 60
8.2 Market Forecasts 61
8.2.1 The US 61
8.2.2 Top Five European Countries 62
8.3 Cost of Vaccination 64
8.3.1 The US 64
8.3.2 Top Five European Countries 64
8.4 Pipeline Analysis – Meningococcal Vaccines 65
9 Adult and Adolescent Vaccines Market to 2018: Human Papilloma Virus Vaccines 67
9.1 Disease Overview 67
9.2 Market Forecasts 68
9.2.1 The US 68
9.2.2 Top Five European Countries 69
9.2.3 Japan 71
9.3 Cost of Vaccination 72
9.3.1 The US 72
9.3.2 Top Five European Countries 72
9.3.3 Japan 73
9.4 Pipeline Analysis – Human Papillomavirus Vaccines 74
10 Adult and Adolescent Vaccines Market to 2018: Hepatitis Vaccines 75
10.1 Disease Overview 75
10.2 Market Forecasts 76
10.2.1 The US 76
10.2.2 Top Five European Countries 77
10.2.3 Japan 79
10.3 Cost of Vaccination 80
10.3.1 The US 80
10.3.2 Top Five European Countries 80
10.3.3 Japan 81
10.4 Pipeline Analysis – Hepatitis Vaccines 82
11 Adult and Adolescent Vaccines Market to 2018: Measles, Mumps and Rubella Vaccines 85
11.1 Disease Overview 85
11.2 Market Forecasts 86
11.2.1 The US 86
11.2.2 Top Five European Countries 87
11.2.3 Japan 89
11.3 Cost of Vaccination 90
11.3.1 The US 90
11.3.2 Top Five European Countries 90
11.3.3 Japan 91
12 Adult and Adolescent Vaccines Market to 2018: Zoster Vaccines 92
12.1 Disease Overview 92
12.2 Market Forecasts 93
12.2.1 The US 93
12.2.2 The UK 94
12.3 Cost of Vaccination 94
12.3.1 The US 94
12.3.2 The UK 94
12.4 Pipeline Analysis – Zoster Vaccines 95
13 Adult and Adolescent Vaccines Market to 2018: Varicella Vaccines 96
13.1 Disease Overview 96
13.2 Market Forecasts 96
13.2.1 The US 96
13.2.2 Top Five European Countries 98
13.2.3 Japan 100
13.3 Cost of Vaccination 101
13.3.1 The US 101
13.3.2 Top Five European Countries 101
13.3.3 Japan 102
13.4 Pipeline Analysis – Varicella Vaccines 102
14 Adult and Adolescent Vaccines Market to 2018: Competitive Landscape 103
14.1 Introduction 103
14.2 Major Company Profiles 103
14.2.1 GlaxoSmithKline 103
14.2.2 Sanofi 105
14.2.3 Pfizer 106
14.2.4 Merck 107
14.2.5 Novartis 108
15 Adult and Adolescent Vaccines Market to 2018: Strategic Consolidations 109
15.1 Deals by Year 109
15.2 Deals by Type 110
15.3 Deals by Value 111
15.4 Deals by Geography 112
15.5 Summary of Major M&A Deals 113
15.6 Summary of Major Licensing Deals 115
15.7 Summary of Major Partnerships 116
16 Adult and Adolescent Vaccines Market to 2018: Appendix 118
16.1 Market Definitions 118
16.2 Abbreviations 118
16.3 Bibliography 120
16.4 Research Methodology 121
16.4.1 Coverage 121
16.4.2 Secondary Research 121
16.4.3 Primary Research 122
16.4.4 Model for Estimation of Vaccine Market 122
16.5 Geographical Landscape 124
16.6 Pipeline Analysis 124
16.7 Competitive Landscape 124
16.7.1 Expert Panel Validation 124
16.8 Contact Us 124
16.9 Disclaimer 124

List of Tables
1.1 List of Tables
Table 1: Adult and Adolescent Vaccines Market to 2018, Vaccine-preventable Diseases, 2012 15
Table 2: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Revenue ($bn), 2007–2011 25
Table 3: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2011–2018 26
Table 4: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, the US, Revenue ($m), 2007–2011 33
Table 5: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, The US, Revenue Forecast ($m), 2011–2018 33
Table 6: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Revenue ($m), 2007–2011 34
Table 7: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011–2018 35
Table 8: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Revenue ($m), 2007–2011 36
Table 9: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Revenue Forecast ($m), 2011–2018 36
Table 10: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, the US, Cost of Vaccination ($), 2007–2011 37
Table 11: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, the US, Cost of Vaccination Forecast ($), 2011–2018 37
Table 12: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007–2011 38
Table 13: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 38
Table 14: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Cost of Vaccination ($), 2007–2011 38
Table 15: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Cost of Vaccination Forecast ($), 2011–2018 38
Table 16: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Global, Pipeline by Phase, 2012 40
Table 17: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Revenue ($m), 2007–2011 43
Table 18: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Revenue Forecast ($m), 2011–2018 43
Table 19: Adult and Adolescent Vaccines Market to 2018, Td/ Tdap, Top Five European Countries, Revenue ($m), 2007–2011 44
Table 20: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Top Five European Countries, Revenue Forecast ($m), 2011–2018 45
Table 21: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Revenue ($m), 2007–2011 46
Table 22: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Revenue Forecast ($m), 2011–2018 46
Table 23: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Cost of Vaccination ($), 2007–2011 47
Table 24: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Cost of Vaccination Forecast ($), 2011–2018 47
Table 25: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Top Five European Countries, Cost of Vaccination ($), 2007–2011 47
Table 26: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 47
Table 27: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Cost of Vaccination ($), 2007–2011 48
Table 28: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Cost of Vaccination Forecast ($), 2011–2018 48
Table 29: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Global, Pipeline by Phase, 2012 49
Table 30: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Revenue ($m), 2007–2011 51
Table 31: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Revenue Forecast ($m), 2011–2018 51
Table 32: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Revenue ($m), 2007–2011 53
Table 33: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011–2018 54
Table 34: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Revenue ($m), 2007–2011 55
Table 35: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Revenue Forecast ($m), 2011–2018 55
Table 36: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Cost of Vaccination ($), 2007–2011 56
Table 37: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Cost of Vaccination Forecast ($), 2011–2018 56
Table 38: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007–2011 56
Table 39: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 56
Table 40: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Cost of Vaccination ($), 2007–2011 57
Table 41: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Cost of Vaccination Forecast ($), 2011–2018 57
Table 42: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Global, Pipeline by Phase, 2012 59
Table 43: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Revenue ($m), 2007–2011 61
Table 44: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Revenue Forecast ($m), 2011–2018 61
Table 45: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Revenue ($m), 2007–2011 62
Table 46: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011–2018 63
Table 47: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Cost of Vaccination ($), 2007–2011 64
Table 48: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Cost of Vaccination Forecast ($), 2011–2018 64
Table 49: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007–2011 64
Table 50: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 64
Table 51: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Global, Pipeline by Phase, 2012 66
Table 52: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Revenue ($m), 2007–2011 68
Table 53: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Revenue Forecast ($m), 2011–2018 68
Table 54: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Revenue ($m), 2007–2011 69
Table 55: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011–2018 70
Table 56: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Japan, Revenue Forecast ($m), 2010–2018 71
Table 57: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Cost of Vaccination ($), 2007–2011 72
Table 58: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Cost of Vaccination Forecast ($), 2011–2018 72
Table 59: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007–2011 72
Table 60: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 72
Table 61: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Japan, Cost of Vaccination Forecast ($), 2009–2018 73
Table 62: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Global, Pipeline by Phase (%), 2012 74
Table 63: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Revenue ($m), 2007–2011 76
Table 64: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Revenue Forecast ($m), 2011–2018 76
Table 65: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Revenue ($m), 2007–2011 77
Table 66: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011–2018 78
Table 67: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Revenue ($m), 2007–2011 79
Table 68: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Revenue Forecast ($m), 2011–2018 79
Table 69: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Cost of Vaccination ($), 2007–2011 80
Table 70: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Cost of Vaccination Forecast ($), 2011–2018 80
Table 71: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007–2011 80
Table 72: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 80
Table 73: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Cost of Vaccination ($), 2007–2011 81
Table 74: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Cost of Vaccination Forecast ($), 2011–2018 81
Table 75: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Global, Pipeline by Phase, 2012 83
Table 76: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Revenue ($m), 2007–2011 86
Table 77: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Revenue Forecast ($m), 2011–2018 86
Table 78: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Revenue ($m), 2007–2011 87
Table 79: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011–2018 88
Table 80: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Japan, Revenue ($m), 2007–2011 89
Table 81: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Japan, Revenue Forecast ($m), 2011–2018 89
Table 82: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Cost of Vaccination ($), 2007–2011 90
Table 83: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Cost of Vaccination Forecast ($), 2011–2018 90
Table 84: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007–2011 90
Table 85: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 90
Table 86: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007–2011 91
Table 87: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 91
Table 88: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Revenue ($m), 2007–2011 93
Table 89: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Revenue Forecast ($m), 2011–2018 93
Table 90: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the UK, Revenue Forecast ($m), 2011–2018 94
Table 91: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Cost of Vaccination ($), 2007–2011 94
Table 92: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Cost of Vaccination Forecast ($), 2011–2018 94
Table 93: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the UK, Cost of Vaccination Forecast ($), 2012–2018 94
Table 94: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, Global, Pipeline by Phase, 2012 95
Table 95: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Revenue ($m), 2007–2011 97
Table 96: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Revenue Forecast ($m), 2011–2018 97
Table 97: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Revenue ($m), 2007–2011 98
Table 98: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Revenue Forecast ($m), 2011–2018 99
Table 99: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Japan, Revenue ($m), 2007–2011 100
Table 100: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Japan, Revenue Forecast ($m), 2011–2018 100
Table 101: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Cost of Vaccination ($), 2007–2011 101
Table 102: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Cost of Vaccination Forecast ($), 2011–2018 101
Table 103: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Cost of Vaccination ($), 2007–2011 101
Table 104: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 101
Table 105: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Japan, Cost of Vaccination ($), 2007–2011 102
Table 106: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Cost of Vaccination Forecast ($), 2011–2018 102
Table 107: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Global, Pipeline by Phase, 2012 102

List of Figures
1.2 List of Figures
Figure 1: Adult and Adolescent Vaccines Market to 2018, Global, Types of Vaccines, 2012 16
Figure 2: Adult and Adolescent Vaccines Market to 2018, The US, Recommendations for Immunization (19–65+ Years), 2012 17
Figure 3: Adult and Adolescent Vaccines Market to 2018, the US, Recommendations for Immunization (7–18 Years), 2012 18
Figure 4: Adult and Adolescent Vaccines Market to 2018, Top Five European Countries, Recommendations for Immunization, 2012 19
Figure 5: Adult and Adolescent Vaccines Market to 2018, Japan, Recommendations for Immunization (Under 20 Years of Age), 2011 20
Figure 6: Adult and Adolescent Vaccines Market to 2018, Global, Vaccine Manufacturing Process, 2012 24
Figure 7: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Revenue Forecast ($bn), 2007–2018 25
Figure 8: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Market Share by Type of Vaccines (%), 2011 27
Figure 9: Adult and Adolescent Vaccines Market to 2018, Top Seven Markets, Market Share by Geography (%), 2011 28
Figure 10: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, the US, Revenue Forecast ($m), 2007–2018 33
Figure 11: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007–2018 34
Figure 12: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Japan, Revenue Forecast ($m), 2007–2018 36
Figure 13: Adult and Adolescent Vaccines Market to 2018, Influenza Vaccines, Global, Pipeline by Phase (%), 2012 39
Figure 14: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, the US, Revenue Forecast ($m), 2007–2018 43
Figure 15: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Top Five European Countries, Revenue Forecast ($m), 2007–2018 44
Figure 16: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Japan, Revenue Forecast ($m), 2007–2018 46
Figure 17: Adult and Adolescent Vaccines Market to 2018, Td/Tdap, Global, Pipeline by Phase (%), 2012 49
Figure 18: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, the US, Revenue Forecast ($m), 2007–2018 51
Figure 19: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007–2018 53
Figure 20: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Japan, Revenue Forecast ($m), 2007–2018 55
Figure 21: Adult and Adolescent Vaccines Market to 2018, Pneumococcal Vaccines, Global, Pipeline by Phase (%), 2012 58
Figure 22: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, the US, Revenue Forecast ($m), 2007–2018 61
Figure 23: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007–2018 62
Figure 24: Adult and Adolescent Vaccines Market to 2018, Meningococcal Vaccines, Global, Pipeline by Phase (%), 2012 65
Figure 25: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, the US, Revenue Forecast ($m), 2007–2018 68
Figure 26: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007–2018 69
Figure 27: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Japan, Revenue Forecast ($m), 2010–2018 71
Figure 28: Adult and Adolescent Vaccines Market to 2018, HPV Vaccines, Global, Pipeline by Phase (%), 2012 74
Figure 29: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, the US, Revenue Forecast ($m), 2007–2018 76
Figure 30: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007–2018 77
Figure 31: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Japan, Revenue Forecast ($m), 2007–2018 79
Figure 32: Adult and Adolescent Vaccines Market to 2018, Hepatitis Vaccines, Global, Pipeline by Phase (%), 2012 82
Figure 33: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, the US, Revenue Forecast ($m), 2007–2018 86
Figure 34: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007–2018 87
Figure 35: Adult and Adolescent Vaccines Market to 2018, MMR Vaccines, Japan, Revenue Forecast ($m), 2007–2018 89
Figure 36: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, the US, Revenue Forecast ($m), 2007–2018 93
Figure 37: Adult and Adolescent Vaccines Market to 2018, Zoster Vaccines, Global, Pipeline by Phase (%), 2012 95
Figure 38: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, the US, Revenue Forecast ($m), 2007–2018 96
Figure 39: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Top Five European Countries, Revenue Forecast ($m), 2007–2018 98
Figure 40: Adult and Adolescent Vaccines Market to 2018, Varicella Vaccines, Japan, Revenue Forecast ($m), 2007–2018 100
Figure 41: Adult and Adolescent Vaccines Market to 2018, GSK, SWOT Analysis, 2012 104
Figure 42: Adult and Adolescent Vaccines Market to 2018, Sanofi, SWOT Analysis, 2012 105
Figure 43: Adult and Adolescent Vaccines Market to 2018, Pfizer, SWOT Analysis, 2012 106
Figure 44: Adult and Adolescent Vaccines Market to 2018, Merck, SWOT Analysis, 2012 107
Figure 45: Adult and Adolescent Vaccines Market to 2018, Novartis, SWOT Analysis, 2012 108
Figure 46: Adult and Adolescent Vaccines Market to 2018, Global, Strategic Consolidations, Deals by Year, 2009–2012 109
Figure 47: Adult and Adolescent Vaccines Market to 2018, Global, Strategic Consolidations, Deals by Type, 2009–2012 110
Figure 48: Adult and Adolescent Vaccines Market to 2018, Global, Strategic Consolidations, Deals by Value, 2009–2012 111
Figure 49: Adult and Adolescent Vaccines Market to 2018, Global, Strategic Consolidations, Deals by Geography, 2009–2012 112
Figure 50: GBI Research Market Forecasting Model 123

Title Date Price
2013 Deep Research Report on China Human Use Rabies Vaccine Industry
By QYResearch
2013 Deep Research Report on China Human Use Rabie Vaccine Industry is a professional and depth research report on China Human Use Rabies Vaccine industry. This report has firstly introduced Human Use ...Read More
Jan 2013 $2000.00
Abdominal Obesity-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abdominal Obesity-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establ ...Read More
$1250.00
Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abortion- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abortion-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Abscess- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed ...Read More
$2000.00
Abscess-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Abscess-Pipeline Insights, 2014
By Delveinsight
SUMMARYDelveInsight’s,“ Abscess-Pipeline Insights, 2014”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the un ...Read More
$1250.00
Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Absence Seizure- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and m ...Read More
$2000.00
Absence Seizure-API Insights, 2014
By Delveinsight
SummaryThe active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large numb ...Read More
$1250.00
Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
By Delveinsight
DelveInsight’s, “ Acid Indigestion / Heartburn/ Pyrosis- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase II ...Read More
$2000.00

  * Required field
Name *
E-mail *
Telephone 
Company *
Country *
Query 
 
   

   
For support please
contact:
US Toll Free
+1 888-789-6604
Asia Pacific
+91-9893555190
 
 
To receive alerts about
an update, future offers and discounts on this report, signup here.
Email ID
 

Companies


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Countries


A B C D E F G H I J K L M N O P Q R S T U V W X Y Z